论文部分内容阅读
目的:评价替比夫定与多烯磷脂酰胆碱联用对慢性乙型肝炎患者的临床疗效。方法:选取确诊为慢性乙肝患者134例,将其分为对照组和观察组(每组67例),对照组患者予替比夫定治疗,观察组患者予替比夫定和多烯磷脂酰胆碱治疗。比较两组患者治疗后的临床疗效。结果:治疗24周后,两组患者的HBV-DNA转阴率、HBe Ag血清学转换率经比较其差异无统计学意义(P>0.05),观察组患者的ALT复常率高于对照组(P<0.05);治疗36周后,观察组患者的ALT复常率、HBV-DNA转阴率及HBe Ag血清学转换率均高于对照组(P<0.05)。结论:替比夫定与多烯磷脂酰胆碱联用对慢性乙型肝炎患者的疗效优于单用替比夫定。
Objective: To evaluate the clinical efficacy of telbivudine and polyene phosphatidylcholine in patients with chronic hepatitis B. Methods: A total of 134 patients with chronic hepatitis B were selected and divided into control group and observation group (67 cases in each group). Patients in the control group were treated with bivalirudin. Patients in the observation group were treated with bupivacaine and polyene phosphatidyl Choline treatment. The clinical efficacy of the two groups after treatment was compared. Results: After 24 weeks of treatment, the rates of HBV DNA negative conversion and HBeAg seroconversion in the two groups had no significant difference (P> 0.05), and the ALT normalization rate in the observation group was higher than that in the control group (P <0.05). After 36 weeks of treatment, ALT normalization rate, HBV-DNA negative rate and HBeAg seroconversion rate in the observation group were higher than those in the control group (P <0.05). Conclusion: The effect of telbivudine combined with polyene phosphatidylcholine is superior to telbivudine alone in patients with chronic hepatitis B.